Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 30:13:1115241.
doi: 10.3389/fonc.2023.1115241. eCollection 2023.

DNA repair deficiency as circulating biomarker in prostate cancer

Martina Catalano  1 , Daniele Generali  2 , Marta Gatti  3 , Barbara Riboli  3 , Leda Paganini  3 , Gabriella Nesi  4 , Giandomenico Roviello  4
Affiliations
Review

DNA repair deficiency as circulating biomarker in prostate cancer

Martina Catalano et al. Front Oncol. .

Abstract

Deleterious aberrations in DNA repair genes are actionable in approximately 25% of metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination repair (HRR) is the DNA damage repair (DDR) mechanism most frequently altered in prostate cancer; of note BRCA2 is the most frequently altered DDR gene in this tumor. Poly ADP-ribose polymerase inhibitors showed antitumor activity with a improvement in overall survival in mCRPC carrying somatic and/or germline alterations of HHR. Germline mutations are tested on peripheral blood samples using DNA extracted from peripheral blood leukocytes, while the somatic alterations are assessed by extracting DNA from a tumor tissue sample. However, each of these genetic tests have some limitations: the somatic tests are related to the sample availability and tumor heterogeneity, while the germline testing are mainly related to the inability to detect somatic HRR mutations. Therefore, the liquid biopsy, a non-invasive and easily repeatable test compared to tissue test, could identified somatic mutation detected on the circulating tumor DNA (ctDNA) extracted from a plasma. This approach should better represent the heterogeneity of the tumor compared to the primary biopsy and maybe helpful in monitoring the onset of potential mutations involved in treatment resistance. Furthermore, ctDNA may inform about timing and potential cooperation of multiple driver genes aberration guiding the treatment options in patients with mCRPC. However, the clinical use of ctDNA test in prostate cancer compared to blood and tissue testing are currently very limited. In this review, we summarize the current therapeutic indications in prostate cancer patients with DDR deficiency, the recommendation for germline and somatic-genomic testing in advanced PC and the advantages of the use liquid biopsy in clinical routine for mCRPC.

Keywords: DNA damage repair; circulating biomarker; circulating tumor DNA; liquid biopsy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Main mechanisms of DNA repair.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S. Genetic aberrations of dna repair pathways in prostate cancer: Translation to the clinic. Int J Mol Sci (2021) 22(18):9783. doi: 10.3390/ijms22189783 - DOI - PMC - PubMed
    1. Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N. Aberrations of DNA repair pathways in prostate cancer: A cornerstone of precision oncology. Expert Opin Ther Targets (2021) 25:329–33. doi: 10.1080/14728222.2021.1951226 - DOI - PubMed
    1. Burdak-Rothkamm S, Mansour WY, Rothkamm K. DNA Damage repair deficiency in prostate cancer. Trends Cancer (2020) 6:974–84. doi: 10.1016/j.trecan.2020.05.011 - DOI - PubMed
    1. Merseburger AS, Waldron N, Ribal MJ, Heidenreich A, Perner S, Fizazi K, et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: A pragmatic guide for clinicians. Eur Urol (2021) 79:519–29. doi: 10.1016/j.eururo.2020.12.039 - DOI - PubMed
    1. Schiewer MJ, Knudsen KE. DNA Damage response in prostate cancer. Cold Spring Harbor Perspect Med (2019) 9(1):a030486. doi: 10.1101/cshperspect.a030486 - DOI - PMC - PubMed